United States of America, ex rel, et al v. Novartis Pharmaceuticals Corporation

  1. March 23, 2016

    Relator Nets Another $66M Payday In Novartis Kickback Suit

    The former Novartis Pharmaceutical Corp. sales manager who helped reveal the company's patient referral kickback scheme was awarded $66.4 million for his part in the drugmaker's $390 million settlement of its portion of the False Claims Act case, according to a New York federal court order Tuesday.

  2. February 01, 2016

    Whistleblower Nets $12.2M Payday In Accredo Kickback Suit

    The former Novartis Pharmaceutical Corp. sales manager who blew the whistle on the company's patient referral kickback scheme was awarded $12.2 million on Friday for his part in specialty pharmacy Accredo Health Group Inc.'s $60 million settlement of its portion of the False Claims Act case, according to an order in New York federal court.

  3. November 20, 2015

    Novartis Faces Strict Pharmacy Oversight In $390M Deal

    Novartis on Friday made detailed admissions about its sales strategies with specialty pharmacies and agreed to sweeping federal oversight of its relationships with the controversial dispensers, capping off a mammoth False Claims Act case that includes a $390 million payout.

  4. October 27, 2015

    All Eyes On DOJ As Novartis FCA Deal Takes Shape

    Novartis AG's tentative settlement Tuesday of kickback allegations for $390 million marked yet another huge False Claims Act payout that wasn't accompanied by punishment for individuals, and any final deal could indicate how aggressively the U.S. Department of Justice will enforce its threats to prosecute Big Pharma management for fraud.

  5. October 27, 2015

    Novartis Inks $390M FCA Deal Over Pharmacy Discounts

    Novartis AG on Tuesday said it has tentatively agreed to shell out $390 million to end a whistleblower's False Claims Act suit alleging improper kickbacks to pharmacies to boost sales of several prescription drugs.

  6. August 12, 2015

    Novartis Says Docs Request In $3.3B FCA Suit Is Too Late

    The whistleblower bringing a $3.35 billion False Claims Act case against Novartis Pharmaceutical Corp. should not be granted access to more employee files than he already has been, as he had enough time to ask for them earlier, the pharmaceutical company told a New York federal judge Tuesday.

  7. August 04, 2015

    Judge Slams Pretrial 'Squabbles' In $3.35B Novartis FCA Suit

    The New York federal judge overseeing a $3.35 billion False Claims Act case against Novartis Pharmaceutical Corp. had harsh words Monday for attorneys positioning for the upcoming trial, warning she would not referee their scheduling "squabbles."

  8. July 06, 2015

    Life Sciences Cases To Watch In The 2nd Half Of 2015

    The pharmaceutical industry is poised for important court developments involving off-label marketing, biosimilars exclusivity, False Claims Act liability and the 340B drug-discount program. Here are four cases that attorneys will be tracking closely in the second half of 2015.

  9. June 30, 2015

    US Demands Up To $3.35B From Novartis In FCA Suit

    The government is seeking up to $3.35 billion in a False Claims Act suit accusing Novartis Pharmaceutical Corp. of paying illegal kickbacks to pharmacies to recommend iron-reduction drug Exjade and transplant drug Myfortic, according to filings in New York federal court.

  10. June 02, 2015

    States Want In On New Charges Against Novartis In Exjade Suit

    Eight states on Monday expanded their allegations against Novartis Pharmaceutical Corp. in an illegal kickback suit, saying they would now like to add their voices to charges that the pharmaceutical giant paid yet another pharmacy to recommend iron-reduction drug Exjade.